Molecular Partners Presents Initial Results of MP0533 Clinical Trial for AML
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 10 hour ago0mins
- Clinical Trial Progress: As of September 1, 2025, 54 patients have been treated with MP0533, with 8 out of 48 evaluable patients achieving a response, including 5 reaching composite complete responses, indicating the drug's potential efficacy in acute myeloid leukemia (AML) patients.
- Dosing Optimization Effects: The accelerated dosing regimen of MP0533 has shown good tolerability and significantly improved serum exposure in treatment cycle 1, suggesting that this approach may provide better treatment options for patients with low disease burden.
- Broad Research Prospects: Investigators recommend further exploration of MP0533's potential in front-line AML treatment, particularly in combination with existing therapies, which could significantly enhance patient outcomes.
- Increased Collaboration Opportunities: Several research consortia have expressed strong interest in further studies of MP0533, and Molecular Partners is actively engaging with potential partners and regulators to advance the next phase of development for this innovative therapy.
MOLN.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on MOLN
Wall Street analysts forecast MOLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOLN is 8.33 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.515
Low
4.00
Averages
8.33
High
12.00
Current: 4.515
Low
4.00
Averages
8.33
High
12.00
JPMorgan
Richard Vosser
Neutral
downgrade
$4
2025-09-03
Reason
JPMorgan
Richard Vosser
Price Target
$4
2025-09-03
downgrade
Neutral
Reason
JPMorgan analyst Richard Vosser lowered the firm's price target on Molecular Partners to $4 from $4.50 and keeps a Neutral rating on the shares.
See All Ratings
About MOLN
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the key findings from the MP0533 clinical trial for AML?
How does the accelerated dosing regimen improve MP0533's effectiveness in AML treatment?
What is the likelihood of MP0533 becoming a front-line treatment for AML?
How might MP0533 perform when combined with existing AML therapies?